WO2005113781A3 - Vectors for use in gene and cancer therapy - Google Patents

Vectors for use in gene and cancer therapy Download PDF

Info

Publication number
WO2005113781A3
WO2005113781A3 PCT/GB2005/002016 GB2005002016W WO2005113781A3 WO 2005113781 A3 WO2005113781 A3 WO 2005113781A3 GB 2005002016 W GB2005002016 W GB 2005002016W WO 2005113781 A3 WO2005113781 A3 WO 2005113781A3
Authority
WO
WIPO (PCT)
Prior art keywords
peptide
serine
gene
vectors
derivative
Prior art date
Application number
PCT/GB2005/002016
Other languages
French (fr)
Other versions
WO2005113781A2 (en
Inventor
Pierre Boulanger
Leif Lindholm
Maria Magnusson
Saw See Hong
Manuel Rosa-Calatrava
Original Assignee
Got A Gene Ab
Habib Nagy
Centre Nat Rech Scient
Pierre Boulanger
Leif Lindholm
Maria Magnusson
Saw See Hong
Manuel Rosa-Calatrava
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Got A Gene Ab, Habib Nagy, Centre Nat Rech Scient, Pierre Boulanger, Leif Lindholm, Maria Magnusson, Saw See Hong, Manuel Rosa-Calatrava filed Critical Got A Gene Ab
Publication of WO2005113781A2 publication Critical patent/WO2005113781A2/en
Publication of WO2005113781A3 publication Critical patent/WO2005113781A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10345—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein

Abstract

The present invention relates to a vector comprising a nucleic acid molecule and a peptide or peptide derivative, said peptide or peptide derivative comprising a peptide of general Formula (I) R1-R2-R3-R4-R5-R6 wherein: R1 is arginine or lysine; R2 is glutamine or asparagine; R3 is methionine; R4 is serine Or threonine; R5 is histidine, tryptophan, arginine or lysine; and R6 is valine, leucine or isoleucine; or a functionally active fragment thereof and a vector comprising a nucleic acid molecule and a peptide or peptide derivative, said peptide or peptide derivative comprising a peptide of general Formula (III) R1-R2-R3-R4-R5-R6-R7-R8-R9-R10 wherein: R1 is threonine; R2 is alanine; R3 is tyrosine; R4 is Serine; R5 is serine R6 is tyrosine R7 is any amino acid, R8 is any amino acid; R9 is glycine; and R10 is glycine or a functionally active fragment thereof and uses thereof in gene cancer
PCT/GB2005/002016 2004-05-21 2005-05-23 Vectors for use in gene and cancer therapy WO2005113781A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0411428.6A GB0411428D0 (en) 2004-05-21 2004-05-21 Vectors
GB0411428.6 2004-05-21

Publications (2)

Publication Number Publication Date
WO2005113781A2 WO2005113781A2 (en) 2005-12-01
WO2005113781A3 true WO2005113781A3 (en) 2006-11-23

Family

ID=32607779

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2005/002016 WO2005113781A2 (en) 2004-05-21 2005-05-23 Vectors for use in gene and cancer therapy

Country Status (2)

Country Link
GB (1) GB0411428D0 (en)
WO (1) WO2005113781A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11845925B2 (en) 2010-07-06 2023-12-19 Glaxosmithkline Biologicals Sa Immunisation of large mammals with low doses of RNA
US11850305B2 (en) 2010-07-06 2023-12-26 Glaxosmithkline Biologicals Sa Method of making lipid formulations with RNA encoding immunogens

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3243526T (en) 2010-07-06 2020-02-10 Glaxosmithkline Biologicals S.A. Delivery of rna to trigger multiple immune pathways
ES2918649T3 (en) 2010-08-31 2022-07-19 Glaxosmithkline Biologicals Sa Pegylated liposomes for delivery of RNA encoding an immunogen
BR112013008700B8 (en) 2010-10-11 2022-10-04 Novartis Ag SELF-REPLICATING RNA MOLECULE, ALPHAVIRUS REPLICON PARTICLE, COMPOSITION, RECOMBINANT DNA MOLECULE, USE OF SELF-REPLICATING RNA MOLECULE
WO2013006838A1 (en) 2011-07-06 2013-01-10 Novartis Ag Immunogenic combination compositions and uses thereof
KR102089121B1 (en) 2013-03-14 2020-03-13 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 Oncolytic adenovirus compositions
AU2017222568B2 (en) 2016-02-23 2020-09-10 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
KR20220163505A (en) 2016-02-23 2022-12-09 솔크 인스티튜트 포 바이올로지칼 스터디즈 Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
AU2017375633C1 (en) 2016-12-12 2023-04-27 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
FONTANA L ET AL: "General strategy for broadening adenovirus tropism", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 77, no. 20, October 2003 (2003-10-01), pages 11094 - 11104, XP002297319, ISSN: 0022-538X *
GADEN FLORENCE ET AL: "Mechanism of restriction of normal and cystic fibrosis transmembrane conductance regulator-deficient human tracheal gland cells to adenovirus infection and ad-mediated gene transfer.", AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY. NOV 2002, vol. 27, no. 5, November 2002 (2002-11-01), pages 628 - 640, XP002363034, ISSN: 1044-1549 *
KOIZUMI NAOYA ET AL: "Generation of fiber-modified adenovirus vectors containing heterologous peptides in both the HI loop and C terminus of the fiber knob.", THE JOURNAL OF GENE MEDICINE. APR 2003, vol. 5, no. 4, April 2003 (2003-04-01), pages 267 - 276, XP002363035, ISSN: 1099-498X *
KRASNYKH V N ET AL: "Genetic targeting of adenoviral vectors", MOLECULAR THERAPY, ACADEMIC PRESS, SAN DIEGO, CA,, US, vol. 1, no. 5 Pt 1, May 2000 (2000-05-01), pages 391 - 405, XP002297322, ISSN: 1525-0016 *
NICKLIN STUART A ET AL: "In vitro and in vivo characterisation of endothelial cell selective adenoviral vectors.", THE JOURNAL OF GENE MEDICINE. MAR 2004, vol. 6, no. 3, March 2004 (2004-03-01), pages 300 - 308, XP002363037, ISSN: 1099-498X *
OGAWARA KEN-ICHI ET AL: "A novel strategy to modify adenovirus tropism and enhance transgene delivery to activated vascular endothelial cells in vitro and in vivo.", HUMAN GENE THERAPY. MAY 2004, vol. 15, no. 5, May 2004 (2004-05-01), pages 433 - 443, XP002363036, ISSN: 1043-0342 *
ROMANCZUK H ET AL: "Modification of an adenoviral vector with biologically selected peptides: a novel strategy for gene delivery to cells of choice.", HUMAN GENE THERAPY. 1 NOV 1999, vol. 10, no. 16, 1 November 1999 (1999-11-01), pages 2615 - 2626, XP002363033, ISSN: 1043-0342 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11845925B2 (en) 2010-07-06 2023-12-19 Glaxosmithkline Biologicals Sa Immunisation of large mammals with low doses of RNA
US11850305B2 (en) 2010-07-06 2023-12-26 Glaxosmithkline Biologicals Sa Method of making lipid formulations with RNA encoding immunogens
US11851660B2 (en) 2010-07-06 2023-12-26 Glaxosmithkline Biologicals Sa Immunisation of large mammals with low doses of RNA

Also Published As

Publication number Publication date
WO2005113781A2 (en) 2005-12-01
GB0411428D0 (en) 2004-06-23

Similar Documents

Publication Publication Date Title
WO2005113781A3 (en) Vectors for use in gene and cancer therapy
JP2013537907A5 (en)
JP2006525288A5 (en)
WO2008057463A3 (en) Peptide-based conditioners
TW200509899A (en) Amino acid composition and supplemental solution
JP2009539952A5 (en)
JP2004521123A5 (en)
NZ579566A (en) Modified fgf-21 polypeptides and their uses
JP2009504135A5 (en)
EP1908492A4 (en) Metabotropic glutamate receptor activator
WO2007065691A3 (en) Small peptidic and peptido-mimetic affinity ligands for factor viii and factor viii-like proteins
CA2215827A1 (en) O-malonyltyrosyl compounds, o-malonyltyrosyl compound-containing peptides, and uses thereof
DE602005025141D1 (en) Cell-penetrating peptides as carriers for molecules
JP2021506815A5 (en)
HK1088849A1 (en) Blood-viscosity reducing agent
KR970005043B1 (en) Tumor necrosis factor alpha muteins
ES2834125T3 (en) Synthesis of beta-turn peptidomimetic cyclic compounds
ES2576959T9 (en) Template-fixed peptidomimetics as FPR1 inhibitors
CN113278045A (en) Polypeptide C (sp) guided by natural amino acid3) Method for arylation or alkynylation modification of-H bond
CN110536696B (en) PCSK9 vaccine based on novel peptides
WO2001009174A3 (en) Plant defensin variants
JP2003286168A5 (en)
US9334314B2 (en) Peptide compounds derived from melanotransferrin and uses thereof
Fang et al. Recent Progress in Electrochemical Modification of Amino acids and Peptides
WO2004064780A3 (en) Peptide-based angiogenesis inhibitors and methods of use thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase